Phase 2 N=22 Sildenafil for Treatment of Choroidal Ischemia
Choroidal Ischemia · Vitelliform Macular Dystrophy · Age-related Macular Degeneration
Primary: Change in Visual Acuity (Sildenafil Group) — 0.00; -0.03 logMAR
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=15 Circadian Macular Volume Changes in the Choroid
Choroid Physiology
Primary: Macular Choroidal Volume — 10.33 mm^3
Phase 1 N=7 Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial
Choroidal Neovascularization
Primary: Number of Subjects Avoiding 15 or More Letter Loss of Best Corrected Visual Acuity From Baseline to 12 Months on an Early Treatment Diabetic Retinopathy Study (ETDRS)…
Phase 1 N=2 Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy
Nonarteritic Anterior Ischemic Optic Neuropathy
Primary: Change in Visual Acuity — 4; 3 lines change in Snellen chart
Phase 4 N=49 Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab
Exudative Age-related Macular Degeneration
Primary: Caliber of Choroidal New Vessel (CNV) — 43.53 micrometer
N/A N=129 Optical Coherence Tomography Angiography Evaluation of Ocular Changes in Patients With Carotid Artery Stenosis
Carotid Stenosis
Primary: Radical Peripapillary Capillaries Vessel Density — 55.95; 57.24 percentage of vessel
Phase 4 N=31 Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO
Retinal Vein Occlusion · Diabetic Macular Edema · Branch Retinal Vein Occlusion
Primary: Change in Panretinal Leakage Index at Month 12 From Baseline — -3.14 percentage of region of interest in UWFA
Phase 3 N=295 Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration
Neovascular Age-Related Macular Degeneration
Primary: Number of Patients With no Disease Activity at Week 16 in the Study Eye — 89 Participants
Phase 3 N=169 Efficacy and Safety of BIIB111 for the Treatment of Choroideremia
Choroideremia
Primary: Percentage of Participants With a ≥15 -Letter Improvement From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12 as Measured by the Early Treatment of Diabetic…
N/A N=40 Citicoline in Non-Arteritic Ischemic Optic Neuropathy
Non-arteritic Ischemic Optic Neuropathy
Primary: Change From Baseline in Visual Acuity at 9 Month — -0.0574; 0.0535 LogMAR
N/A N=5 Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema
Uveitis · Cystoid Macular Edema
Primary: Improvement in VA ETDRS >/= 15 Letters — 1 participants
N/A N=49 The Efficacy of Normobaric Oxygen on Chronic Cerebral Ischemia
Normobaric Oxygen · Cerebral Ischemia
Primary: The Fronto-central Theta Absolute Power Change Rate — 0.14; -0.12 ratio
N/A N=100 Evaluation of Retinal Microvascular Change That May Develop in After Open Globe Injury
Eye Injury Trauma
Primary: Corneal Thickness — 542.23; 546.16; 544.32 microns
N/A N=10 Intraocular Pressure During Abdominal Aortic Aneurysm (AAA) Repair
Problem With Vision Blindness · Intraocular Pressure · Ischemic Optic Neuropathy
Primary: Right Intraocular Pressure During Various Event Intervals in Open Abdominal Aortic Aneurysm Surgery. — 16.9; 13.8; 14.6; 13.5 mm Hg — p=<0.001
Phase 4 N=30 Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion
Central Retinal, Hemi Retinal & Brach Retinal Vein Occlusions
Primary: Total Number of Intravitreal Injections Over a 12 Month Period — 8.7; 9.5 injections
Phase 3 N=200 A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.
Choroidal Neovascularization Secondary to Pathologic Myopia
Primary: Number of Patients Treated and Re-treated Based on Presence/Absence of Active Leakage — 3; 0; 61; 121 Patients — p=<0.0001
Phase 3 N=277 Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
Pathological Myopia
Primary: Average Change From Baseline to Month 1 Through Month 3 on Visual Acuity of the Study Eye — 55.4; 55.8; 54.7; 66.0 Letters
Phase 2 N=88 Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Choroidal Neovascularization · Age-related Macular Degeneration
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye at Month 3 — .3; 6.8; 7.6 Letters
Phase 2 N=4 A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)
Idiopathic Polypoidal Choroidal Vasculopathy
Primary: Number of Participants With >15 ETDRS Letter Loss at Month 3 — 0 Participants
Phase 3 N=160 Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis
Uveitis · Uveitis, Posterior · Uveitis, Anterior
Primary: Number of Subjects Demonstrating ≥ 15 Letter Improvement From Baseline in Best Corrected Visual Acuity at 24 Weeks — 45; 10 Participants — p=<0.001
N/A N=30 A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion
Central Retinal Vein Occlusion
Primary: Change From Baseline in Visual Acuity Using Early Treatment Diabetic Retinopathy Study (ETDRS) Charts — 12.5; 14; 13.5 letters read correctly
Phase 3 N=38 Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis
Uveitis · Uveitis, Posterior · Uveitis, Anterior
Primary: Adverse Events — 27; 1 Participants
Phase 2 N=6 Choroideremia Gene Therapy Clinical Trial
Choroideremia
Primary: Change in Best Corrected Visual Acuity From Baseline — 3.0 Letters
Phase 4 N=333 Aflibercept in Polypoidal Choroidal Vasculopathy
Neovascular Macular Degeneration
Primary: Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment of Diabetic Retinopathy Study (ETDRS) Letter Scores From Baseline to Week 52 - Last…
Phase 2 N=25 Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema
Diabetic Macular Edema
Primary: Frequency of Ocular Adverse Events, Systemic Adverse Events, Serious, and Treatment-emergent Non-serious Adverse Events — 10; 8; 3; 5 Participants
Phase 2 N=6 High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia
Retinal Diseases · Telangiectasis
Primary: Visual Acuity Change From Baseline to Month 12 of the Study — 0.1; -0.05 LogMAR Unit
Phase 3 N=122 VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)
Myopia, Pathological
Primary: Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) From Baseline to Week 24 - Last Observation Carried…
Phase 3 N=457 Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)
Primary: Change From Baseline BCVA to the Average Level of BCVA Over All Monthly Assessments From Month 1 to Month 3 — 53.7; 54.2; 52.6; 63.1 ETDRS letters — p=<0.001
N/A N=46 The Effects of an Antioxidant Formulation on Ocular Blood Flow
Primary Open Angle Glaucoma
Primary: Change in Superior Retinal Capillary Blood Flow (% Zero Pixels) — -0.026; 0.011 % zero pixels — p=0.0016
Phase 3 N=178 Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.
Choroidal Neovascularization (CNV)
Primary: Change From Baseline in Best-corrected Visual Acuity (BCVA) in Study Eye to Month 2 — 9.5; -0.4 letters — p=<0.001